Search Results
Your search for ,WHo matches 20675 pages
Showing 19851 - 19900ASCO 2014: Adding Docetaxel to Androgen-Deprivation Therapy Significantly Improves Survival in Hormone-Sensitive Prostate Cancer
The addition of docetaxel to androgen-deprivation therapy extended survival for men with newly diagnosed hormone-sensitive prostate cancer by more than 13 months in the National Cancer Institute–led phase III E3805 study. The survival benefit was even greater for men with high-volume disease. ...
ASCO 2014: Adjuvant Exemestane With Ovarian Function Suppression Better at Preventing Breast Cancer Recurrence Than Tamoxifen
A joint analysis of two phase III trials demonstrated that the aromatase inhibitor exemestane more effectively prevents breast cancer recurrences than tamoxifen when either was given with ovarian function suppression to premenopausal women with hormone-sensitive cancers. Exemestane plus ovarian...
ASCO 2014: Addition of Chemotherapy to Radiotherapy Improves Survival in Low-Grade Glioma
In a long-term follow-up analysis of RTOG 9802, the addition of PCV (procarbazine [Matulane], lomustine [CeeNu], and vincristine) to radiotherapy prolonged both progression-free survival and overall survival in adult patients with low-grade glioma. The findings were reported at the 2014 ASCO Annual ...
ASCO 2014: Ibrutinib Significantly Delays Disease Progression and Extends Survival in Relapsed CLL
Early findings from the phase III RESONATE study indicate that ibrutinib (Imbruvica) produces durable tumor responses and marked improvement in survival over standard ofatumumab (Arzerra) for patients with relapsed chronic lymphocytic leukemia (CLL). “With ibrutinib, about 80% of patients...
ASCO 2014: Second-Line Treatment With Ramucirumab Plus Standard Docetaxel Extends Overall Survival in Advanced Lung Cancer
Patients with stage IV non–small cell lung cancer (NSCLC) who relapsed after initial platinum-based therapy experienced extended overall survival with a combination of the antiangiogenic agent ramucirumab (Cyramza) and standard chemotherapy with docetaxel, compared to patients receiving...
ASCO 2014: Investigational Anti–PD-L1 Antibody Demonstrates Promising Activity in Certain Patients With Metastatic Bladder Cancer
In a phase I study, the investigational anti–programmed death-ligand 1 (PD-L1) monoclonal antibody MPDL3280A demonstrated promising overall response rates in patients with previously treated metastatic urothelial bladder cancer whose tumors were characterized as PD-L1–positive. The ...
ASCO 2014: Bortezomib Combination Significantly Improves Progression-Free Survival in Newly Diagnosed Mantle Cell Lymphoma
An international, randomized phase III study found that replacing vincristine with bortezomib (Velcade) in R-CHOP (rituximab [Rituxan] plus cyclophosphamide, doxorubicin, vincristine, and prednisone) significantly improved outcomes in newly diagnosed patients with mantle cell lymphoma who were...
ASCO 2014: Patients With Metastatic Colon Cancer Respond to New Combination Therapy, Phase IB Study Shows
In a new study presented at the 2014 ASCO Annual Meeting in Chicago (Abstract 3516), researchers from The University of Texas MD Anderson Cancer Center found patients with advanced colorectal cancer responded well to a combination therapy of the drugs vemurafenib (Zelboraf), cetuximab (Erbitux),...
ASCO 2014: Women With BRCA Mutations Report Significant Side Effects Following Risk-Reducing Salpingo-Oophorectomy
The majority of women with BRCA1 and BRCA2 mutations experience sexual dysfunction, menopausal symptoms, cognitive and stress issues, and poor sleep following risk-reducing salpingo-oophorectomy, according to results of a new study from the Abramson Cancer Center and the Perelman School of Medicine ...
ASCO 2014: Men Who Receive Radiation Therapy for Prostate Cancer Have Increased Long-Term Risk of Bladder or Rectal Cancer
Men with prostate cancer generally have an excellent prognosis, but questions remain about the risk of second primary malignancies after initial therapy for localized disease. According to a new study presented at the 2014 ASCO Annual Meeting in Chicago (Abstract 5034), although the overall risk of ...
Study Identifies Risk of Chemotherapy-Related Hospitalization for Early-Stage Breast Cancer Patients
Oncologists now have a new understanding of the toxicity levels of specific chemotherapy regimens used for women with early-stage breast cancer, according to research from The University of Texas MD Anderson Cancer Center. The retrospective study, reported in the Journal of Clinical Oncology by...
Greater Risk of Pretreatment Cognitive Impairment in Older Breast Cancer Patients With More Advanced Disease and Greater Comorbidity
In a study reported in the Journal of Clinical Oncology, Mandelblatt and colleagues attempted to determine whether cognitive impairment is present in older patients with breast cancer prior to systemic therapy. They found that although there were no global differences in cognitive function between...
Central Pancreatectomy for Low-Grade Neoplasms Results in 'Excellent' Pancreatic Function but Substantial Morbidity
The availability of cross-sectional imaging has resulted in increased diagnosis of low-grade pancreatic neoplasms and use of central pancreatectomy as an alternative to standard resection for such lesions. In a French single-center experience reported in JAMA Surgery, Goudard et al found that...
Five or More Blistering Sunburns in Early Life May Raise Melanoma Risk by 80%
According to a large study of Caucasian women investigating chronic sun exposure over long durations in adulthood and sun exposure in early life, those who had at least five blistering sunburns when they were 15 to 20 years old had a 68% increased risk for basal cell carcinoma and squamous cell...
Korean Trial Shows Similar Disease-Free Survival With Laparoscopic vs Open Surgery in Mid- or Low-Rectal Cancer After Neoadjuvant Chemoradiotherapy
In the noninferiority COREAN trial reported in The Lancet Oncology, Jeong et al found that laparoscopic surgery was associated with disease-free survival similar to that with open surgery for mid- or low-rectal cancer. Study Details In this open-label trial, 340 patients with cT3N0–2M0...
FDA Approves Palonosetron Hydrochloride to Prevent Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients
The U.S. Food and Drug Administration (FDA) has approved palonosetron hydrochloride (Aloxi) injection for the prevention of acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy, in children aged 1...
ASCO Guideline Update Recommends Tamoxifen for Up to 10 Years for Women With Nonmetastatic Hormone Receptor–Positive Breast Cancer
The American Society of Clinical Oncology (ASCO) has issued an update to its clinical practice guideline on the use of adjuvant endocrine therapy for women with stage I to III hormone receptor–positive breast cancer. The guideline was published in the Journal of Clinical Oncology. Duration...
No Apparent Benefit of Adding Cetuximab to Gemcitabine Plus Oxaliplatin in Advanced Biliary Tract Cancer
Gemcitabine plus a platinum agent is standard treatment in advanced biliary cancer. In the phase II open-label noncomparative BINGO trial, reported in The Lancet Oncology, Malka et al found no apparent benefit of adding the EGFR inhibitor cetuximab (Erbitux) to gemcitabine/oxaliplatin in first-line ...
FDA Approves Panitumumab Plus FOLFOX for Wild-Type KRAS Metastatic Colorectal Cancer
The U.S. Food and Drug Administration (FDA) has approved panitumumab (Vectibix) for use in combination with FOLFOX (fluorouracil, leucovorin, oxaliplatin) as first-line treatment in patients with wild-type KRAS (exon 2) metastatic colorectal cancer. This approval converts the accelerated...
Proactive Patient-Centered Program May Reduce the Risk of Lymphedema in Survivors of Breast Cancer
A patient-centered educational and behavioral program focusing on self-care strategies appears to be an effective way to reduce the risk of lymphedema in survivors of breast cancer, according to the results of a prospective study by Fu et al at New York University. These findings, reported in the...
No Progression-Free or Overall Survival Benefit With Second- or Third-Line Erlotinib vs Docetaxel in EGFR-Unselected Japanese NSCLC Patients
In a Japanese phase III trial (DELTA) reported in the Journal of Clinical Oncology, Kawaguchi et al found that erlotinib (Tarceva) was associated with no progression-free survival or overall survival advantage as second- or third-line therapy in EGFR-unselected patients with non–small cell...
Circulating Tumor Cells Predict Disease-Free Survival and Overall Survival in Patients With Early Average- to High-Risk Breast Cancer
Although presence of circulating tumor cells has been shown to predict reduced survival in metastatic breast cancer, data on their predictive performance in earlier breast cancer are lacking. In a study reported in the Journal of the National Cancer Institute, Rack et al found that presence of...
More Toxicity Associated With Addition of Sorafenib to Yttrium-90 Radioembolization Prior to Liver Transplantation
The addition of sorafenib (Nexavar) to yttrium-90 radioembolization was associated with higher rates of biliary complications and potentially more acute rejections prior to transplantation in patients with hepatocellular carcinoma, according to the results of a prospective randomized pilot study....
No Overall Survival Improvement With Elacytarabine vs Investigator Choice in Patients With Relapsed/Refractory AML
Current treatment options for relapsed/refractory acute myeloid leukemia (AML), which carries a very poor prognosis, are generally ineffective. In a phase III trial (CLAVELA) reported in the Journal of Clinical Oncology, Roboz et al found that elacytarabine, a novel elaidic acid ester of...
Majority of Women Undergoing Contralateral Prophylactic Mastectomy Have No Major Risk Factors for Developing Cancer in Both Breasts
Patients deciding to undergo contralateral prophylactic mastectomy as part of initial treatment for breast cancer is a growing challenge in the management of the disease. Removing the unaffected breast has not been shown to increase survival, and the more aggressive procedure is associated with...
Supportive Tumor Tissue Surrounding Cancer Cells Hinders Pancreatic Cancer Progression, Preclinical Study Reports
Fibrous tissue long suspected of making pancreatic cancer worse actually supports an immune attack that slows tumor progression but cannot overcome it, scientists at The University of Texas MD Anderson Cancer Center reported in the journal Cancer Cell. “This supportive tissue that’s...
Mutations Associated With Arsenic Resistance in Acute Promyelocytic Leukemia
In a letter to The New England Journal of Medicine, Zhu et al described identification of resistance mutations in acute promyelocytic leukemia patients receiving arsenic trioxide (Trisenox) and all-trans retinoic acid (ATRA) therapy. The direct-binding targets of arsenic trioxide in the...
Proteomic Signature for EGFR Inhibitor Therapy Predicts Survival Benefit of Second-Line Chemotherapy vs Erlotinib in NSCLC
There are conflicting data on whether epidermal growth factor receptor (EGFR) inhibitor therapy is beneficial in second-line treatment of lung cancer patients with unknown or wild-type EGFR status. In a phase III trial (PROSE) reported in The Lancet Oncology, Gregorc et al assessed the predictive...
The Cancer Community Mourns the Passing of Selma Schimmel
The cancer community is mourning the death of Selma Schimmel who passed away on May 21, 2014, from malignant psoas syndrome, a complication of ovarian cancer. Ms. Schimmel died at Providence Tarzana Medical Center near her home in Los Angeles, California. She was 59. A tireless and fierce advocate ...
Study Uses Comprehensive Genomic Tumor Testing to Match Lung Cancer Patients With Targeted Therapies
In a recent study by the Lung Cancer Mutation Consortium (LCMC), investigators incorporated tumor genotyping into therapeutic decision-making for patients with lung adenocarcinomas. An oncogenic driver was detected in 64% of tumors from patients in this study. According to data from this study...
Study Reveals More Than One-Third of Patients With ‘Low-Risk’ Prostate Cancer on Conventional Biopsy Have More Aggressive Tumors on Targeted Biopsy
According to a new study by researchers at the University of California, Los Angeles, selection of men for active surveillance for prostate cancer should be based not on conventional biopsy, but on a new, imaging-guided targeted prostate biopsy. The new biopsy method is now a routine part of the...
Insulin-Like Growth Factor-1 Score Improves Assessment of Prognosis in Hepatocellular Carcinoma
In a study reported in the Journal of the National Cancer Institute, Kaseb et al developed a plasma insulin-like growth factor 1 (IGF-1)–based score for hepatic reserve in hepatocellular carcinoma and compared its predictive ability with that of the Child-Turcotte-Pugh (CTP) score in two...
High Expression of Brachyury Associated With Poor Prognosis in Breast Cancer Patients Receiving Adjuvant Tamoxifen
Epithelial-mesenchymal transition plays a key role in tumor cell invasion, metastasis, and drug resistance and the transcription factor brachyury has recently been identified as a driver of this process. In a study reported in the Journal of the National Cancer Institute, Palena et al found that a...
Study Suggests Less Frequent Cardiac Screening May Be Preferable for Survivors of Childhood Cancer
One of the first studies to analyze the effectiveness of screening survivors of childhood cancer for early signs of impending congestive heart failure found improved health outcomes but suggested that less frequent screening than currently recommended may yield similar clinical benefit. Researchers ...
Low Use of Chemotherapy in Last 14 Days of Life at MD Anderson Cancer Canter
A proposed metric of quality of cancer care is whether chemotherapy is administered in the last 14 days of life. In a retrospective study of patients at The University of Texas MD Anderson Cancer Center reported in JAMA Internal Medicine, Rodriguez et al found an overall rate of chemotherapy use in ...
Radium-223 Dichloride Significantly Prolongs Time to First Symptomatic Skeletal Event in Patients With Castration-Resistant Prostate Cancer
In an article in The Lancet Oncology, Sartor et al report symptomatic skeletal event outcomes in the phase III ALSYMPCA trial, which was the study supporting the May 2013 approval of radium-233 dichloride (Xofigo) in patients with castration-resistant prostate cancer and bone metastases. They found ...
Early Study Shows Improved Survival With Radioimmunotherapy/Gemcitabine Combination in Patients With Advanced Pancreatic Ductal Cancer
A randomized phase Ib study of a combination of low radiosensitizing doses of gemcitabine and fractionated doses of 90Y-clivatuzumab tetraxetan in patients with metastatic pancreatic ductal cancer who had received at least two prior systemic therapies, has found a significant survival advantage in...
Studies Evaluate Racial Variations, Cost, and Influence of Access to Care in the Management and Treatment of Testicular Cancer
A series of studies evaluating the cost-effectiveness, risks, and outcomes associated with detecting, diagnosing, and treating testicular cancer were presented at a press conference during the 2014 Annual Scientific Meeting of the American Urological Association in Orlando, Florida. Although...
Results of Three Studies Indicate 17-Gene Assay Is a Significant Predictor of Prostate Cancer Aggressiveness at the Time of Diagnosis
According to the results from three studies published in European Urology, the 17-gene Oncotype DX Genomic Prostate Score is a significant predictor of disease aggressiveness at the time of diagnosis before intervention with radiation or surgery. The test provides more precise and individualized...
IASLC/American Thoracic Society/European Respiratory Society Classification of Lung Adenocarcinoma Has Predictive Value for Recurrence and Survival
In a study reported in the Journal of Clinical Oncology, Hung et al assessed the ability of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society (IASLC/ATS/ERS) adenocarcinoma classification system to predict disease recurrence and...
Neoadjuvant Dose-Dense Methotrexate, Vinblastine, Doxorubicin, Cisplatin With Pegfilgrastim: Safe and Effective in Muscle-Invasive Urothelial Cancer
In a phase II trial reported in the Journal of Clinical Oncology, Choueiri et al found that a neoadjuvant four-cycle/8-week regimen of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin was well tolerated and effective in patients with muscle-invasive urothelial cancer. Study Details ...
U.S. Cervical Cancer Rates Higher Than Previously Reported, Particularly Among Older Women and African American Women
Cervical cancer rates in the United States are higher than previously believed, particularly among 65- to 69-year-old women and African American women, according to a study by Rositch et al published in Cancer. Current U.S. cervical cancer screening guidelines do not recommend routine Pap smears...
Frequent but Nontargeted Use of Pharmacologic Thromboprophylaxis in Hospitalized Patients With Cancer
Retrospective studies have shown that pharmacologic thromboprophylaxis is underutilized in hospitalized patients with cancer, who are believed to be at high risk of venous thromboembolism. In a prospective cross-sectional study reported in Journal of Clinical Oncology, Zwicker et al found that...
Carcinogens Found in Water Pipe Smoking May Increase Risk for Cancer
Researchers investigating the effects of water pipe smoking on the health of young adults have found elevated levels of nicotine, cotinine, tobacco-related cancer-causing agents, and volatile organic compounds, including benzene and acrolein, in the urine of users. Given the significant intake of...
Necitumumab Plus Chemotherapy Shows Overall Survival Benefit in Patients With Squamous NSCLC
In the large phase III SQUIRE trial of necitumumab (IMC-11F8) in combination with gemcitabine and cisplatin in the first-line treatment of advanced squamous non–small cell lung cancer (NSCLC), patients with stage IV metastatic disease showed a statistically significant improvement in overall...
Obesity Substantially Increases Breast Cancer Mortality Only in Women With Premenopausal Estrogen Receptor–Positive Disease
A new study of 80,000 women with early breast cancer in 70 clinical trials finds that obesity is associated with a 34% higher risk of breast cancer–related death only among the 20,000 premenopausal women who had estrogen receptor–positive disease. Obesity had little effect in...
Study Projects Nationwide Low-Dose CT Screening Will Identify More—and Earlier-Stage—Lung Cancers, but Comes With Substantial Medicare Costs
A new model projects 5-year outcomes of implementing the recent U.S. Preventive Services Task Force (USPSTF) recommendations for annual low-dose computed tomography (CT) lung cancer screening in a high-risk Medicare population. The model estimates that gradual implementation of the screening...
New EGFR Inhibitor AZD9291 Shows Promising Activity in Treatment-Resistant Non–Small Cell Lung Cancer
Findings from a phase I study of a new mutant-selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, AZD9291, point to a promising new treatment option for patients with advanced, EGFR-mutant, non–small cell lung cancer (NSCLC) that is resistant to standard EGFR...
Delaying Androgen Deprivation Therapy May Be Safe for Men With Prostate Cancer Relapse Detected by PSA Testing
According to a large, population-based observational study of men who had a prostate-specific antigen (PSA)-only based relapse after prostate surgery or radiation therapy, delaying androgen deprivation therapy until the onset of symptoms or appearance of cancer on a scan does not substantially...
Novel Target Found for Chemotherapy-Resistant Leukemia Cells
Researchers at Children’s Hospital Los Angeles have discovered that by targeting a particular receptor, chemotherapy-resistant cancer cells can be killed in an acute form of childhood leukemia, offering the potential for a future treatment for patients who would otherwise experience relapse...
